Targeted protein degraders crowd into the clinic

Unlocking precision medicine: Innovative strategies for druggable target identification and therapeutic enhancement

Liao, Y., Wei, Z., Xu, H., Zhang, Z., & Zhu, F. (2024) · Precision medication. · doi:10.1016/j.prmedi.2024.10.002 · Cited by 4

Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation

Ibrahim, S., Khan, M. U., Noreen, S., Firdous, S., Khurram, I., Rehman, R., Javed, M. A., & Ali, Q. (2025) · Cytotechnology · doi:10.1007/s10616-025-00716-8 · Cited by 3

Ubiquitin Proteasome Gene Signatures in Ependymoma Molecular Subtypes

Vriend, J. P., Thanasupawat, T., Sinha, N., & Klonisch, T. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012330 · Cited by 3

Advancing PROTAC Characterization: Structural Insights through Adducts and Multimodal Tandem-MS Strategies

Rahman, M. K., Marzullo, B. P., Holman, S. W., Barrow, M. P., Ray, A. D., & O’Connor, P. B. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.3c00342 · Cited by 4

The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis

Wei, Y., Wu, B., Liu, M., & Cui, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168870 · Cited by 4

Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives

Yan, X. Y., Kang, Y. Y., Zhang, Z. Y., Huang, P. C., Yang, C., & Naranmandura, H. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2443577 · Cited by 3

Facile Synthesis of Homodimeric Protein Ligands

Gui, W., & Kodadek, T. J. (2023) · ChemBioChem · doi:10.1002/cbic.202300392 · Cited by 3

Pharmacology of PROTAC Degrader Molecules

Pike, A., Guzzetti, S., Gutierrez, P. M., & Scott, J. S. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch11 · Cited by 3

Rapid PROTAC discovery platform: nanomole scale array synthesis and direct screening of reaction mixtures to facilitate the expedited discovery and follow-up of PROTAC hits.Preprint

Plesniak, M. P., Taylor, E. K., Eisele, F., Kourra, C. M. B. K., Michaelides, I. N., Oram, A., Wernevik, J., Valencia, Z. S., Rowbottom, H., Mann, N., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-dz9l7 · Cited by 3

Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier

Sexton, J. Z. (2022) · doi:10.64628/aai.dftakmwj7 · Cited by 3

Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs

Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 4

Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics

Zhang, Q., Liu, Q., Liu, J., Zhang, T., Wang, H., Shu, L., Wang, Y., Yang, T., Zhuang, R., Hong, L., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115145 · Cited by 2

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming

Song, Y., Yang, C., Li, Q., Huang, S., Chen, S., Xia, Z., Yao, X., Sheng, C., & Dong, G. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00454 · Cited by 2

The Latest Advancements of the PROTACs Based on CRBN E3 Ligase for Cancer Treatment

Stadnichenko, V. O., Borysko, P., & Tolstanova, G. M. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00409-y · Cited by 2

Emerging pharmacology of targeted protein degraders

Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2

Advances in AR-Targeting Chimeras: A Case Study of proteolysis-targeting Chimeras From Bench to Bedside

Du, W. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0147 · Cited by 2

Biochemical Principles of Targeted Protein Degradation

Agafonov, R. V., Deibler, R. W., Elam, W. A., Patel, J. S., & Fisher, S. L. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch10 · Cited by 2

Strategies for Tag‐Based Protein Control

Nabet, B., Gray, N. S., & Ferguson, F. M. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch13 · Cited by 2

Insights and Future Perspectives of Covalent Protein Degraders

Zhang, X. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch8 · Cited by 2

Targeted Protein Degradation as a Therapeutic Strategy in Neurodegenerative Diseases

Ferguson, F. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch7 · Cited by 2

Cellular Principles of Targeted Protein Degradation

Diamantino, J., & Hellerschmied, D. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch2 · Cited by 2

Modeling the Structures of Ternary Complexes Mediated by Molecular Glues

Drummond, M. L. (2024) · Wiley eBooks · doi:10.1002/9783527840748.ch22 · Cited by 2

Ion channel inhibition by targeted recruitment of NEDD4-2 with divalent nanobodiesPreprint

Morgenstern, T. J., Darko-Boateng, A., Afriyie, E., Shanmugam, S. K., Zhou, X., Choudhury, P., Desai, M., Kass, R. S., Clarke, O. B., & Colecraft, H. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.28.596281 · Cited by 2

Targeting Epigenetic Readers Using Small Molecule Binders and PROTAC Degraders

Boccia, E., Gazzillo, E., Chini, M. G., Bifulco, G., & Lauro, G. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_240 · Cited by 1

The peptidomimetic approach for the design of viral protease inhibitors

Trabocchi, A. (2025) · The Enzymes · doi:10.1016/bs.enz.2025.06.007 · Cited by 1

Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protein Degradation Approaches

Liu, Y., Sun, Y., Song, T.-Y., Ni, S.-Y., Pu, Y.-S., Chang, Y. H., Zhou, W.-X., Peng, Z.-G., Liu, J., Shi, J., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3941 · Cited by 2

Arylidene-Thiazoldione Scaffold Acts as the E3 Ligand of DCAF11 for PROTAC Design

Liang, J., Liu, Y., Zhao, M., Chen, L., Qin, J., Ma, W., Wang, Y., Wu, H., Tian, R., Wei, T., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02188 · Cited by 1

Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review

Rahaman, S. A., Venkateswarlu, G., Patel, S., Mishra, P. S., Kumar, R., & Parvez, N. (2026) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266384226251013054011 · Cited by 1

Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy

Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1

Knowledge mapping and bibliometric insights of scientific research on targeted protein degradation in oncology

Sweileh, M. W. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06482-0 · Cited by 1

A destination-driven framework for nanoparticle-enabled targeted protein degradation

Wang, Y., Xia, X., Xie, S., Tong, F., Liu, W., & Gao, H. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.009 · Cited by 1

Targeted degradation of SETDB1 by an Aptamer-CRBNL PROTAC as a novel therapeutic strategy for breast cancer

Huang, S., Lv, Y., Wang, Y., Duan, Y., Li, S., Guo, Y., Xie, S., Dong, C., Yang, Y., Sun, S.-K., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118982 · Cited by 1

GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency

Tang, Y. H., Zhang, M., Fang, Y., Li, Q., Song, Y., Sheng, C., & Dong, G. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00367 · Cited by 1

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Qin, S., Peng, R., Zhang, G., Yan, S., Xiao, J., Liu, Z., Tan, Z., Xie, Q., Li, S., Luo, W., et al. (2026) · Smart Molecules · doi:10.1002/smo2.70089 · Cited by 2

Novel Technologies in PROTAC Design

Jain, K., Reddy, S. C., Moode, S., Mehra, P., Tarannum, S., Patel, M., Jain, V. K., & Popli, H. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_5 · Cited by 1

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

Shemorry, A., den Besten, W., Mulvihill, M. M., Essenburg, C. J., Blaquière, N., Kleinheinz, T., Villemure, E., Peale, F., Deshmukh, G. S., Maddalo, D., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.008 · Cited by 1

Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy

Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1

PCNA degradation exhibits superior pharmacological effects over stoichiometric inhibition

Basu, A. A., Riha, I. A., & Zhang, X. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.11.004 · Cited by 1

Ternary Kinetic Models for Rational Design of Molecular GluesPreprint

Douglass, E. F., & Miller, C. J. (2021) · ChemRxiv · doi:10.33774/chemrxiv-2021-wgn82 · Cited by 1

Addressing Enzymatic-Independent Tumor-Promoting Function of NAMPT via PROTAC-Mediated DegradationPreprint

Zhu, X., Liu, H., Chen, L., Cang, Y., Jiang, B., Yang, X., & Fan, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.13.460066 · Cited by 1

A Reliable and Sustainable Multicomponent Access to Protein DegradersPreprint

Bhela, I. P., Ranza, A., Serafini, M. T., & Pirali, T. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-440t2 · Cited by 1

Decarbonylative Cross-Electrophile Coupling: Synthesis Of C–C Bonds Instead of C–N Bonds from Carboxylic Acids and AminesPreprint

Wang, J., Ehehalt, L. E., Huang, Z., Beleh, O. M., Guzei, I. A., & Weix, D. J. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-ms1hb · Cited by 1

Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4 DCAF11 RecruitmentPreprint

Wanga, Y., Wei, T., Zhao, M., Huang, A., Sun, F., Chen, L., Lin, R., Xie, Y., Zhang, M., Xu, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.15.580430 · Cited by 1

P4ward: an automated modelling platform for Protac ternary complexesPreprint

Jofily, P., & Kalyaanamoorthy, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.28.625921 · Cited by 1

A Reliable and Sustainable Multicomponent Access to Protein DegradersPreprint

Bhela, I. P., Ranza, A., Serafini, M. T., & Pirali, T. (2021) · doi:10.33774/chemrxiv-2021-440t2-v2

Apoptosis, necroptosis, and pyroptosis in health and disease

Liao, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00008-7

Spatial dimension and demographic dynamics of Kenyas urban subsystem.

Obudho, R. A. (1976)

A Reliable and Sustainable Multicomponent Access to Protein DegradersPreprint

Bhela, I. P., Ranza, A., Serafini, M. T., & Pirali, T. (2021) · doi:10.33774/chemrxiv-2021-440t2

Comparative analysis of NX-2127 and ibrutinib in treating B-cell malignancies

Subin, J. (2022) · STEM Fellowship Journal · doi:10.17975/sfj-2022-008

Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with anti-leukemic activityPreprint

Sinatra, L., Yang, J., Schliehe‐Diecks, J., Dienstbier, N., Voigt, M., Gebing, P., Bachmann, L. M., Sönnichsen, M., Lenz, T., Stühler, K., et al. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-dntx4

Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with anti-leukemic activityPreprint

Sinatra, L., Yang, J., Schliehe‐Diecks, J., Dienstbier, N., Vogt, M., Gebing, P., Bachmann, L. M., Sönnichsen, M., Lenz, T., Stühler, K., et al. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-dntx4-v3

Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery

Martinelli, P., Kofink, C. C., Boeck, G., Weinstabl, H., & Koegl, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch11

Cellular selectivity and kinetics of clinical kinase inhibitors

Berger, L. M. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.72279

A Mild and Sustainable Procedure for the Functionalization of Morpholin-2-Ones by Oxidative Imidation Reactions

Phillips, A. M. F., & Pombeiro, A. J. L. (2023) · Catalysts · doi:10.3390/catal13071072

Probing the DCAF12 interactions with MAGEA3 and CCT5 C-terminal degronsPreprint

Righetto, G. L., Yin, Y., Vu, V., Duda, D. M., Szewczyk, M. M., Zeng, H., Li, Y., Loppnau, P., Mei, T., Li, Y.-Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.15.553295

SMALL-MOLECULE DEGRADERS OF IKAROS ZINC FINGER (IKZF) TRANSCRIPTION FACTORS

Holmberg‐Douglas, N., Shunatona, H. P., Kumi, G. K., & Purandare, A. V. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch10

Superantibiotics to Combat Superbacteris

Górna, M. (2023) · ACADEMIA - The magazine of the Polish Academy of Sciences · doi:10.24425/academiapas.2023.147463

Forced Intracellular Degradation of Xenoantigens: A Novel Modality for Cell-Based Cancer ImmunotherapyPreprint

Rafei, M., Bikorimana, J., Farah, R., Abusarah, J., Erregragui, M. A., Gonçalves, M., Talbot, S., & El-Hachem, N. (2023) · Research Square · doi:10.21203/rs.3.rs-3545973/v1

Chromatin Remodeling Complexes: Arising Opportunities and Challenges of Targeting Chromatin Remodelers

Sandoval, G. J., Gioacchini, N., Wu, L., Kalogeropulou, A. F., Hesler, S. J., Taherbhoy, A. M., Netherton, M. R., Bellon, S. F., & Daniels, D. L. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00473

Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets

(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part3

Forced Intracellular Degradation of Xenoantigens as a Novel Modality for Cell-Based Cancer ImmunotherapyPreprint

Bikorimana, J., Farah, R., Abusarah, J., Mandl, G. A., Erregragui, M. A., Pereira, M. A., Talbot, S., Matar, P., Lahrichi, M., El-Hachem, N., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5013530

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy

Bikorimana, J., Farah, R., Abusarah, J., Mandl, G. A., Erregragui, M. A., Gonçalves, M. P., Talbot, S., Matar, P., Lahrichi, M., El-Hachem, N., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111957

Characterization of PROTACs by Ternary Complex Landscape Exploration using Monte Carlo simulationsPreprint

Díaz-Rovira, A. M., Perez‐Lopez, C., Martín-Pérez, J., Pallara, C., Díaz, L., & Guallar, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.11.648328

Discovery of ERα-targeting PROTACs with intrinsic fluorescence for precision theranostics of breast cancer

Wu, Y., Dai, J., Deng, X., He, P., Liang, J., Xin, L., Xie, B., Zhu, S., Dong, C., & Zhou, H. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00281h

Research Progress in Hematological Malignancies: A Molecular Genetics Perspective

Kansal, R. (2025) · Genes · doi:10.3390/genes16060663

Harnessing the power of traditional Chinese medicine for targeted protein degradation

Wu, Z., Zhu, B., Shou, Y., & Guo, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00011-7

Protease-mediated degradation

Yang, L., Duan, H., Mao, X., Li, B., Che, J., & Dong, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00004-x

Comparison of the antibacterial properties of peptides from the hepatopancreas of red king crab and snow crab and development of an approach for red king crab peptide isolation from the hepatopancreas

Molchanov, V., Yunusova, A. K., Kazantseva, O. A., Yegorov, A. Y., Lukin, A., Timchenko, A., Novikov, V. Y., Novojilov, N., & Timchenko, M. (2025) · PeerJ · doi:10.7717/peerj.19989

Emerging Approaches for Targeted Protein Degradation

(2025) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.45.03.10

Design, synthesis and biological evaluation of macrocyclic NTRK heterobifunctional degraders

Anderson, C., Tsai, J. H.-C., Ingham, O. J., Deibler, R. W., Kreger, B. T., Chaturvedi, P., Hung, K. Y. S., Nasveschuk, C. G., Henderson, J. A., & Sowa, M. E. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130516

Emerging Drug Modalities Redefining Small-Molecule Therapeutics: Antibody–Drug Conjugates, Protacs, and Molecular Glues

V.Geetha (2026) · International Journal of Latest Technology in Engineering Management & Applied Science · doi:10.51583/ijltemas.2026.15020000071

New Generations of Antibodies and Scaffold Proteins as a Way to Create Highly Selective Conjugates for Oncology

Shulcheva, I. V., & Ulitin, A. B. (2026) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00305

Membrane protein folding, misfolding, and quality control

Kim, E., Kim, S., Kim, M., & Min, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-99507-8.00049-4

Predicting PROTAC degradation activity and selectivity of effective E3 ligase through harnessing a combination of AtomPair fingerprints and multiple machine learning algorithms

Pandiyan, S., Zhou, M., Chen, Y., Shao, J., Yao, M., & wang, L. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109449

Photo‐Assisted NanoPROTACs for Targeted Cancer Therapy

Kairui, Y., Rao, H., & Wu, C. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71290

USP13-mediated stabilization of FOXD1 activates aerobic glycolysis to drive osteogenic differentiation and mitigate osteoporosis

Bai, J., Zhang, Y., Jin, M., Qiao, M., Li, L., An, J., Xinsai, L., Li, S., Yang, Y., Wang, A., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118190

A COX-2 PROTAC Nanodrug for osteoarthritis therapy via enhancing cartilage repair and reprogramming macrophage polarization

Li, C., Zhu, S., He, A., Zhu, L., Bao, T., Xia, Y., Li, S., Zhuang, W., Hu, W., & He, C. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115135

BindingDB Entry 50015880: Estimating the cooperativity of PROTAC-induced ternary complexes using

BindingDB (2023) · Discovery Research Portal (University of Dundee) · doi:10.7270/q2cf9v3m

Design of Synthesizable PROTACs through Synthesis Constrained Generative Model and Reinforcement Learning

Xu, M., Huang, C., Pang, L., Deng, Q., Zhang, H., Qiao, A., Luo, Z., Wang, Z., Hsieh, C., Zhang, Z., et al. (2026) · JACS Au · doi:10.1021/jacsau.6c00732 · Cited by 2

Future of Medicine: How Small Molecules and Biologics Complement Each Other─A Medicinal Chemist’s Perspective

Hadianawala, M., Mohanty, S. K., & Patil, S. N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02013

HiBiT-RR and nLucK0 Tagging Systems for Monitoring Targeted Protein Degradation

Lin, H., Qi, X., & Wang, J. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5508-5_1

E3 ubiquitin ligases orchestrate chemo-resistance in gastrointestinal malignancies: from DNA damage response to therapeutic targeting

Ma, T., 周永宁, Li, X., & Guan, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1835284

Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents

Panda, S. S., Bekheit, M. S., Aboshouk, D. R., Sivakumar, S., Morsy, M. A., Abdur-Rahman, M., Fahmi, A., & Girgis, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188007

Proteolysis Targeting Chimeras (PROTACs): Design and Mechanism

Lin, X., Zhang, Y., & Wang, C. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_838

An artificial antibody-based modular platform for targeted degradation of cellular membrane proteins

Deng, J., Liu, J., Chu, Z., Guo, Y., Liu, Y.-Y., Gao, T., Wang, Y., Lou, C., Tang, H., Wang, H., et al. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103187

PROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification

Nagmoti, S., Kadam, E., Sakle, N. S., Kapare, H. S., & Karwa, P. N. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04970-1

A patenting perspective of IKZF2 molecular glue degraders (2020-present)

Zhang, X. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2748593

Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma

Chen, X., Xu, R., Wang, X., Wu, H., Wang, N., Huang, X., Kang, W., You, Q., Guo, X., & Jiang, Z. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02040

Optimizing Endosomal Escape for Effective Aptamer-Based Ubiquitin-Mediated Degradation of c-Met

Liu, Y., Jiang, M., Li, J., Zhang, L., Zuo, C., Zhang, H., & Tan, W. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c09554

BindingDB Entry 50018808: Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

BindingDB (2024) · UC San Diego · doi:10.7270/q27p93nv

BindingDB Entry 50021218: Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.

BindingDB (2025) · UC San Diego · doi:10.7270/q2nv9pv1

BindingDB Entry 50019886: Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).

BindingDB (2024) · UC San Diego · doi:10.7270/q2nv9pnb

BindingDB Entry 50021897: Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy.

BindingDB (2025) · UC San Diego · doi:10.7270/q2p55t5m

BindingDB Entry 50015814: Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4.

BindingDB (2023) · UC San Diego · doi:10.7270/q2jd51rw

BindingDB Entry 50018142: Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform.

BindingDB (2024) · UC San Diego · doi:10.7270/q2xp7942

BindingDB Entry 50019485: Recent advances in the development of EGFR degraders: PROTACs and LYTACs.

BindingDB (2024) · UC San Diego · doi:10.7270/q2d22301

BindingDB Entry 50021665: The application of PROTAC in HDAC.

BindingDB (2025) · UC San Diego · doi:10.7270/q2474gjr

BindingDB Entry 50019168: Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q2f76hvr

BindingDB Entry 50019736: Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.

BindingDB (2024) · UC San Diego · doi:10.7270/q2dz0dpx

Protein degraders push into novel target space

Mullard, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/d41573-024-00170-9 · Cited by 18

Targeted protein degradation: from mechanisms to clinic

Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438

Targeted protein degraders - new modalities for drug discovery

Hatakeyama, H. (2026) · Drug Delivery System · doi:10.2745/dds.41.93

Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation

Wang, C., Guo, Z., Liu, Y., Gao, Q., Wang, Q., Liu, Y., & Liu, Y. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127323

Targeted protein degradation comes of age

Matyskiela, M. E. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01789-w · Cited by 3